10X Genomics Inc

TXG

18.610USD

+0.910+5.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

10X Genomics Inc's Score

Industry at a Glance

Industry Ranking

59 / 205

Overall Ranking

165 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

10X Genomics Inc Highlights

StrengthsRisks

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.28% year-on-year.

Undervalued

The company’s latest PE is -29.84, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 125.80M shares, decreasing 10.74% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.63K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.35.

Analyst Rating

Based on 17 analysts

Hold

Current Rating

18.071

Target Price

+2.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of 10X Genomics Inc is 7.61, ranking 73 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 149.00M, representing a year-over-year decrease of 1.75%, while its net profit experienced a year-over-year decrease of 23.16%.

Score

Industry at a Glance

Previous score

7.61

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.19

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.48

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.19

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of 10X Genomics Inc is 8.21, ranking 38 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -29.84, which is -81.51% below the recent high of -5.52 and -41.78% above the recent low of -42.31.

Score

Industry at a Glance

Previous score

8.21

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of 10X Genomics Inc is 6.71, ranking 163 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 16.00, with a high of 20.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

6.71

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of 10X Genomics Inc is 6.54, ranking 132 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 22.32 and the support level at 16.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.29

Change

0.25

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of 10X Genomics Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 108.01%, representing a quarter-over-quarter increase of 5.43%. The largest institutional shareholder is The Vanguard, holding a total of 12.99M shares, representing 11.16% of shares outstanding, with 11.71% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

13.25M

+6.72%

ARK Investment Management LLC

Star Investors

11.89M

-14.43%

BlackRock Institutional Trust Company, N.A.

7.78M

+2.57%

Fidelity Management & Research Company LLC

7.21M

-5.64%

Sumitomo Mitsui Trust Bank, Limited

5.38M

-10.58%

Millennium Management LLC

5.44M

+88.57%

Amova Asset Management Co., Ltd.

5.38M

--

Wellington Management Company, LLP

4.29M

+126.60%

Quantinno Capital Management LP

3.49M

+56.37%

BofA Global Research (US)

3.30M

+13.55%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 10X Genomics Inc is 4.85, ranking 94 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

10X Genomics Inc

TXG

7.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Becton Dickinson and Co

BDX

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Align Technology Inc

ALGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment